Epigenetix, Inc.
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies (NCT05488548) | Epigenetix, Inc. | 2022-12-21 |
Track Epigenetix, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.